Voglibose
![Voglibose Structure](CAS/GIF/83480-29-9.gif)
- CAS No.
- 83480-29-9
- Chemical Name:
- Voglibose
- Synonyms
- 5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol;Basen;Jumeal;AO 128;A 71100;Glustat;Beigrace;Voglistat;VOGLIBOSE;Voglibose D5
- CBNumber:
- CB4481287
- Molecular Formula:
- C10H21NO7
- Molecular Weight:
- 267.28
- MOL File:
- 83480-29-9.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/4/24 17:21:45
Melting point | 162-163°C |
---|---|
alpha | D25 +26.2° (c = 1 in water) |
Boiling point | 601.9±55.0 °C(Predicted) |
Density | 1.58±0.1 g/cm3(Predicted) |
storage temp. | -20°C |
solubility | DMSO (Slightly), Methanol (Very Slightly, Heated), Water (Sparingly, Sonicated) |
form | Solid |
pka | 13.26±0.70(Predicted) |
color | White to Off-White |
Merck | 14,10029 |
InChIKey | FZNCGRZWXLXZSZ-CIQUZCHMSA-N |
CAS DataBase Reference | 83480-29-9(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() GHS07 |
---|---|
Signal word | Warning |
Hazard statements | H302-H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
Hazard Codes | Xi |
Risk Statements | 20/21/22-36/37/38 |
Safety Statements | 36/37-37/39-26 |
WGK Germany | 3 |
RTECS | NM7524600 |
HS Code | 2940.00.6000 |
Voglibose price More Price(4)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich(India) | 50359 | Voglibose ≥97.0% (TLC) | 83480-29-9 | 10MG | ₹24616.05 | 2022-06-14 | Buy |
TCI Chemicals (India) | V0119 | Voglibose | 83480-29-9 | 100MG | ₹10900 | 2022-05-26 | Buy |
SRL | 40996 | Voglibose extrapure, 98% | 83480-29-9 | 100mg | ₹4870 | 2022-05-26 | Buy |
SRL | 40996 | Voglibose extrapure, 98% | 83480-29-9 | 500mg | ₹16230 | 2022-05-26 | Buy |
Voglibose Chemical Properties,Uses,Production
Description
Voglibose was introduced in Japan for the treatment of postprandial hyperglycemia in diabetic patients. As an orally active α-D-glucosidase inhibitor, it is effective in decreasing the release of glucose from carbohydrate ingestion and slowing the increase of postprandial blood glucose levels, as demonstrated in animals and humans following sucrose and starch loading. In addlion, voglibose was reported to have prophylactic effect in genetically obese Wistar rats, maintaining low plasma levels of glucose, triglyceride and insulin, indicating a potential usefulness for the management of other carbohydrate-dependent metabolic disorders such as obesity. Voglibose is much more potent and has fewer side effects than acarbose, another agent in its class.
Chemical Properties
Colourless Crystalline Solid
Uses
Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.
World Health Organization (WHO)
Acarbose and voglibose area-glucosidase inhibitors and delay digestion/absorption of carbohydrates as well as improving postprandial hyperglycaemia.
General Description
The most potent -glucosidase inhibitor is the valiolamine derivative voglibose. Compared with acarbose its inhibitory potency in vitro, depending on the -glucosidase enzyme, is up to 200 times higher. In Japan, daily dosages are only 0.3 – 0.9 mg, however, therapeutic efficacy on HbA1c reduction could not be clearly demonstrated with those dosages. HbA1c, a glycated hemoglobin species, which occurs in blood, is a diagnostic measure for the non-enzymatic glycation process, and depends on the plasma glucose concentration. The process of protein glycation is discussed to be responsible for the development of diabetic complications (neuropathy, retinopathy, nephropathy). In Europe voglibose is under evaluation with distinctly higher daily dosages of 1.5 to 6 mg. In contrast to acarbose, the smaller inhibitors of the monosaccharide type (miglitol, emiglitate, voglibose) do not inhibit pancreatic -amylase.
Biological Activity
Orally active α -glucosidase inhibitor (IC 50 values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo .
Voglibose Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
Jigs Chemical ltd | +919099003427 | Gujarat, India | 239 | 58 | Inquiry |
Anthem Biosciences Pvt Ltd | +91-8066724000 +91-9900044575 | Karnataka, India | 38 | 58 | Inquiry |
Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
Horster Biotek Pvt Ltd | +91-7359657360 +91-9898127219 | Gujarat, India | 58 | 58 | Inquiry |
Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
Alfa Omega Pharma | +91-8050045945 +91-9972665399 | Maharashtra, India | 126 | 58 | Inquiry |
Beloorbayir Biotech Ltd | +91-8792661159 +91-8867683718 | Karnataka, India | 25 | 58 | Inquiry |
Allastir Private Limited | +91-9840051621 +91-9791039207 | Tamil Nadu, India | 15 | 58 | Inquiry |
Indexim International | 08048971004 | Gujarat, India | 112 | 58 | Inquiry |
Rag Healthcare | 08048372836Ext 550 | Gujarat, India | 19 | 58 | Inquiry |
Supplier | Advantage |
---|---|
Jigs Chemical ltd | 58 |
Anthem Biosciences Pvt Ltd | 58 |
Hetero Drugs Limited | 58 |
Horster Biotek Pvt Ltd | 58 |
Ralington Pharma | 58 |
Alfa Omega Pharma | 58 |
Beloorbayir Biotech Ltd | 58 |
Allastir Private Limited | 58 |
Indexim International | 58 |
Rag Healthcare | 58 |
Related articles
- Voglibose: Overview, Properties and Synthesis from Valiolamine
- Voglibose is a potent α-glucosidase inhibitor effective against hyperglycemia, obesity, and diabetes, with fewer side effects ....
- Apr 1,2024
- Voglibose: mechanism of action, pharmacokinetics and safety
- Voglibose is a α-glucosidase inhibitor for type 2 diabetes that can regulate blood glucose without causing hypoglycemia and ma....
- Aug 25,2023
- Role of voglibose in prevention of type 2 diabetes
- Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lower....
- Aug 19,2019
83480-29-9(Voglibose)Related Search:
1of4
chevron_right